Catalent (NYSE:CTLT)‘s stock had its “outperform” rating restated by investment analysts at First Analysis in a research report issued on Tuesday, The Fly reports. They currently have a $49.00 target price on the stock. First Analysis’ target price suggests a potential upside of 14.92% from the company’s current price.
Several other brokerages have also recently issued reports on CTLT. ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a research note on Wednesday, February 20th. Morgan Stanley set a $46.00 target price on shares of Catalent and gave the stock a “buy” rating in a research note on Monday, December 3rd. TheStreet raised shares of Catalent from a “c” rating to a “b-” rating in a research note on Wednesday, February 6th. Zacks Investment Research cut shares of Catalent from a “buy” rating to a “hold” rating in a research note on Thursday, February 7th. Finally, Royal Bank of Canada set a $45.00 target price on shares of Catalent and gave the stock a “buy” rating in a research note on Friday, November 16th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Catalent has an average rating of “Buy” and a consensus target price of $47.88.
Catalent stock opened at $42.64 on Tuesday. Catalent has a 1 year low of $29.23 and a 1 year high of $46.43. The firm has a market capitalization of $6.37 billion, a P/E ratio of 26.82, a P/E/G ratio of 2.39 and a beta of 1.66. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.63 and a current ratio of 2.08.
Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, February 5th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.08. Catalent had a net margin of 5.48% and a return on equity of 17.42%. The company had revenue of $623.00 million for the quarter, compared to analysts’ expectations of $608.38 million. During the same quarter in the previous year, the company posted $0.45 EPS. The firm’s quarterly revenue was up 2.8% on a year-over-year basis. As a group, analysts forecast that Catalent will post 1.69 EPS for the current year.
In other Catalent news, SVP William Downie sold 7,315 shares of Catalent stock in a transaction on Friday, February 15th. The shares were sold at an average price of $42.00, for a total transaction of $307,230.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 1.40% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of CTLT. JPMorgan Chase & Co. raised its holdings in shares of Catalent by 29.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock worth $363,316,000 after acquiring an additional 1,819,020 shares during the period. Oregon Public Employees Retirement Fund raised its holdings in shares of Catalent by 3,074.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,798,868 shares of the company’s stock worth $58,000 after acquiring an additional 1,742,199 shares during the period. Norges Bank purchased a new position in shares of Catalent during the 4th quarter worth $47,177,000. Select Equity Group L.P. purchased a new position in shares of Catalent during the 3rd quarter worth $67,646,000. Finally, Vanguard Group Inc. raised its holdings in shares of Catalent by 9.4% during the 3rd quarter. Vanguard Group Inc. now owns 12,925,639 shares of the company’s stock worth $588,763,000 after acquiring an additional 1,110,779 shares during the period. Institutional investors and hedge funds own 96.85% of the company’s stock.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: What is a recession?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.